Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review

Published:2024-09 Issue:9 Volume:30 Page:1026-1040
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Irving Peter M.¹,Hur Peter²,Gautam Raju³,Guo Xiang⁴,Vermeire Severine⁵

Affiliation:

1. Gastroenterology, Guy’s and St Thomas’ Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom.

2. Pfizer Inc, New York City, NY.

3. EVERSANA Pvt. Ltd., Mumbai, Maharashtra, India, now with ConnectHEOR, London, United Kingdom.

4. Pfizer Inc, Collegeville, PA.

5. Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.

Publisher

Academy of Managed Care Pharmacy

Reference111 articles.

1. Crohn’s & Colitis Foundation of America. The facts about inflammatory bowel diseases. 2014. Accessed December 19, 2022. crohnscolitisfoundation.org

2. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders

3. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis

4. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP